Real-time continuous glucose monitoring (CGM) can accelerate glycemic improvement in adults with type 2 diabetes using basal insulin. Findings from the MOBILE study, published in BMJ Open Diabetes Research & Care, showed that replacing blood glucose monitoring (BGM) with CGM led to faster and greater reductions in HbA1c and improved daily glucose stability.

In this 3-month randomized analysis, 175 adults were assigned to either CGM (n=116) or BGM (n=59). Average HbA1c dropped from 9.1% to 8.0% with CGM, compared with 9.0% to 8.5% with BGM, reflecting an adjusted difference of −0.6% (p < 0.001). CGM increased time in range by 9.3% and reduced time above 250 mg/dL by 5.8%, with no rise in time below 70 mg/dL or hypoglycemia events.

Notably, significant CGM improvements emerged within the first week of use, underscoring its potential for more immediate and effective diabetes management in patients treated with basal insulin.